PT. Cordlife Persada

Secure your family's future health with Cordlife Stem Cell banking. Visit now to earn more about umbilical cord blood banking and cord lining banking.
Metascreen

Metascreen^™ is a non-invasive, early detection test specially designed to screen more than 100 inherited metabolic disorders in newborns.
VISIT WEBSITE
Genscreen

Genetic testing uses laboratory techniques to identify possible presence of genetic diseases or gene mutations associated with increased risk of developing certain medical conditions.
VISIT WEBSITE
NICE^®

From a simple blood draw as early as 10 weeks into your pregnancy, NICE® screens for the most common chromosomal abnormalities that can affect your developing baby's future. This test is done with little or no risk to your pregnancy.
VISIT WEBSITE
Prévue^™

A safe and highly accurate NIPT performed to screen for the most common chromosomal abnormalities such as Down syndrome. The test is done through a simple blood draw as early as 10 weeks into your pregnancy
VISIT WEBSITE

~ Certainty Made Easy ~

Prévue^TM PGS (Preimplantation Genetic Screening) is the procedure of evaluating embryos for chromosomal aneuploidy, the presence of either addition or loss of chromosomes in embryos generated from chromosomally normal parents. In conjunction with in vitro fertilization (IVF) treatment, Prevue™ PGS helps to improve the likelihood of a successful pregnancy while reducing the chance of miscarriage or having a child with gross chromosomal disorders.

“Research has shown that transfer an embryo after PGS has higher rate of a successful pregnancy , from 22% to 41%.¹”

Who should consider Prévue^TM PGS

“PGS test is highly beneficial to women above 37 years old. This test helps to improve pregnancy and live birth rate.²”

Women of advanced maternal age

Women with recurrent pregnancy loss

Men with infertility issues

Women with repeated implantation failure

Carriers of chromosomal abnormalities

Mothers who had given birth to a child with chromosomal abnormalities

Why Prévue^TM PGS

Comprehensive Test

Screens all 23 pairs of chromosomes

Employs Next Generation Sequencing (NGS)

screen for embryo aneuploidy and/or DNA gains or losses (larger than 20Mb)

Highest Quality Assurance

Tested by largest prenatal laboratory in Taiwan with CAP-accreditation and illumina CSPro-certified process

Quick Turnaround

Test result will be available within 3 weeks from the date of sample receipt by the laboratory

99.9%³

Accuracy rate

5 simple steps to enrol Prévue^TM PGS

Step 1: Consultation

Consult your doctor or fertility specialist

Step 2: Collection

Doctor or fertility specialist will collect samples (Trophectoderm cells / Blastocyst).

Step 3: Sequence

Your samples will be delivered to the sequencing laboratory in Taiwan for analysis.

Step 4: Report

Reports will be available in 3 weeks.

Step 5: Transfer

Based on the PGS test results, your doctor or fertility specialist will select and transfer healthy embryos to the uterus.

Enquire Now

Prévue ^TM PGS is brought to you by PT Cordlife Persada in partnership with Taiwan-based laboratory - Genetics Generation Advancement Corp. (GGA).

Disclaimer
No test is perfect. A PGS test result is specific to the tested sample. The test result only provides supporting evidence for the healthcare provider, and does not draw final diagnostic conclusions. PGS test result is NOT a diagnostic test. If any chromosomal abnormality (aneuploidy/deletion/duplication) is found, the healthcare provider shall be responsible in providing guidance and recommendations based on the currently known abnormalities. While results of this testing is usually highly conclusive, not all chromosomal abnormalities can be detected depending on the chromosomal or embryonic status or other causes.

Liss J, Pastuszek E, Pukszta S et al. Effect of next-generation sequencing in preimplantation genetic testing on live birth ratio. Reprod Fertil Dev. 2018;30(12):1720-1727.
Kang, Hey-Joo et al. Preimplantation genetic screening: who benefits? Fertility and Sterility. 2016; 106(3):597 – 602. https://www.fertstert.org/article/S0015-0282(16)61124-X/fulltext . Accessed March 5, 2019.
Fiorentino F, Biricik A, Bono S et al. Development and validation of a next-generation sequencing-based protocol for 24-chromosome aneuploidy screening of embryos. Fertil Steril. 2014;101(5):1375-82. https://www.ncbi.nlm.nih.gov/pubmed/24613537 . Accessed December 5, 2019.

PT. Cordlife Persada

Metascreen

Genscreen

NICE^®

Prévue^™

~ Certainty Made Easy ~

“Research has shown that transfer an embryo after PGS has higher rate of a successful pregnancy , from 22% to 41%.¹”

Who should consider Prévue^TM PGS

“PGS test is highly beneficial to women above 37 years old. This test helps to improve pregnancy and live birth rate.²”